Johannes Bükki

Prof. Dr. Johannes Bükki


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
CPCarmelo Pozzo
Carmelo Pozzo
CBC. Barone
C. Barone
JSJ. Szanto
J. Szanto
EPE. Padi
E. Padi
CPC. Peschel
C. Peschel
RBR. Bugat
R. Bugat
Background: To identify the most effective of two combinations, irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) and irinotecan/cisplatin, in the treatment of advanced gastric cancer, for investigation in a phase III trial. Patients and methods: Patients were randomized to receive irinotecan [80 mg/m2 intravenously (i.v.)], FA (500 mg/m2 i.v.) and a 22-h infusion of 5-FU (2000 mg/m2 i.v.), weekly for 6 weeks with a 1-week rest, or irinotecan (200 mg/m2 i.v.) and cisplatin (60 mg/m2 i.v.), on day 1 for 3 weeks. Results: A total of 115 patients were eligible for analysis in the per-protocol population. The overall response rate in the irinotecan/5-FU/FA arm (n=59) was 42.4%, with a complete response rate of 5.1%. Corresponding figures for the irinotecan/cisplatin arm (n=56) were 32.1% and 1.8%, respectively. The median time to progression was 6.5 months (irinotecan/5-FU/FA) and 4.2 months (irinotecan/cisplatin) (P < 0.0001), with median survival times of 10.7 and 6.9 months, respectively (P=0.0018). The major toxicity was grade 3/4 neutropenia, which was more pronounced with irinotecan/cisplatin than with irinotecan/5-FU/FA (65.7% versus 27%). Diarrhea was the main grade 3/4 non-hematological toxicity with both irinotecan/5-FU/FA (27.0%) and irinotecan/cisplatin (18.1%). Conclusions: Both combinations were active, with acceptable safety profiles. Irinotecan/5-FU/FA was selected as the most effective combination for investigation in a phase III trial in advanced gastric cancer.

1 January 2013 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
OLOlav Lindqvist
Olav Lindqvist
GLGunilla Lundquist
Gunilla Lundquist
ADAndrew Dickman
Andrew Dickman
Johannes BükkiJohannes Bükki
Johannes Bükki
ULUrska Lunder
Urska Lunder
OFOn Behalf Of Opcare9 Carl Johan Fürst
On Behalf Of Opcare9 Carl Johan Fürst
The majority of dying patients do not have access to necessary drugs to alleviate their most common symptoms, despite evidence of drug efficacy. Our aim was to explore the degree of consensus about appropriate pharmacological treatment for common symptoms in the last days of life for patients with cancer, among physicians working in specialist palliative care. Within OPCARE9, a European Union seventh framework project aiming to optimize end-of-life cancer care, we conducted a Delphi survey among 135 palliative care clinicians in nine countries. Physicians were initially asked about first and second choice of drugs to alleviate anxiety, dyspnea, nausea and vomiting, pain, respiratory tract secretions (RTS), as well as terminal restlessness. Based on a list of 35 drugs mentioned at least twice in the first round (n=93), a second Delphi round was performed to determine ≤ 5 essential drugs for symptom alleviation in the last 48 hours of life that should be available even outside specialist palliative care. There was ≥ 80% consensus among the participants (n=90) regarding morphine, midazolam, and haloperidol as essential drugs. For RTS, there was consensus about use of an antimuscarinic drug, with 9%-27% of the physicians each choosing one of four different drugs. Based on this consensus opinion and other literature, we suggest four drugs that should be made available in all settings caring for dying patients with cancer, to decrease the gap between knowledge and practice: morphine (i.e., an opioid), midazolam (a benzodiazepine), haloperidol (a neuroleptic), and an antimuscarinic.

1 January 2011 in Breast Care
Verified
Journal Article
Closed access
PDF file
TMThomas Merz
Thomas Merz
CKCarsten Klein
Carsten Klein
BUBarbara Uebach
Barbara Uebach
MKMartina Kern
Martina Kern
COChristoph Ostgathe
Christoph Ostgathe
Johannes BükkiJohannes Bükki
Johannes Bükki
The management of fungating, malignant wounds is a challenge for the palliative care team. Open, malodorous, poorly healing lesions are obvious signs of underlying disease. In addition, pain and functional impairment remind the patients of their incurable illness. A multidimensional approach is necessary to meet the needs of these patients and to improve quality of life. Although achieving wound closure is rarely a realistic goal, modern techniques of wound management can help to minimize odours and exudates. Specialist knowledge in palliative care is needed to provide adequate pain control. Psychosocial support may help patients to cope with the situation and their limited abilities.

3 August 2014 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
Johannes BükkiJohannes Bükki
Johannes Bükki
TUT. Unterpaul
T. Unterpaul
GNG. Nübling
G. Nübling
RJR. J. Jox
R. J. Jox
SLS. Lorenzl
S. Lorenzl

17 September 2023 in Journal of Pain and Symptom Management
Verified
Journal Article
Open access
SPStefan Pitzer
Stefan Pitzer
PKPatrick Kutschar
Patrick Kutschar
PPPiret Paal
Piret Paal
PMPatrick Mülleder
Patrick Mülleder
SLStefan Lorenzl
Stefan Lorenzl
Johannes BükkiJohannes Bükki
Johannes Bükki
Access to palliative care services is variable, and many inpatients do not receive palliative care. An overview of potential barriers could facilitate the development of strategies to overcome factors that impede access for patients with palliative care needs. To review the current evidence on barriers that impair, delay, or prohibit access to palliative care for adult hospital inpatients. A mixed methods systematic review was conducted using an integrated convergent approach and thematic synthesis (PROSPERO ID: CRD42021279477). The Cochrane Library, MEDLINE, CINAHL, and PsycINFO were searched from 10/2003 to 12/2020. Studies with evidence of barriers for inpatients to access existing palliative care services were eligible and reviewed. After an initial screening of 3,359 records and 555 full-texts, 79 studies were included. Thematic synthesis yielded 149 access-related phenomena in 6 main categories: (1) Sociodemographic characteristics, (2) Health-related characteristics, (3) Individual beliefs and attitudes, (4) Inter-individual cooperation and support, (5) Availability and allocation of resources, and (6) Palliative care-specific challenges. While evidence was inconclusive for most socio-demographic factors, the following barriers emerged: having a non-cancer condition or a low symptom burden, the focus on cure in hospitals, non-acceptance of terminal prognosis, negative perceptions of palliative care, misleading communication and conflicting care preferences, lack of resources, poor coordination, insufficient expertise, and clinicians' emotional discomfort and difficult prognostication. Hospital inpatients face multiple barriers to accessing palliative care. Strategies to address these barriers need to take into account their multidimensionality and long-standing persistence.

30 December 2014 in American Journal of Hospice and Palliative Medicine®
Verified
Journal Article
Closed access
Johannes BükkiJohannes Bükki
Johannes Bükki
GNGeorg Nübling
Georg Nübling
SLStefan Lorenzl
Stefan Lorenzl
Background: Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are characterized by rapid deterioration and a fatal outcome. Objectives: Admission triggers, treatment efficacy, and care patterns. Methods: Retrospective analysis of patients with PSP/CBD admitted to an inpatient specialized palliative care service. Results: In 38 patients, there were 63 admissions for swallowing difficulties, falls, pain, impaired communication, cognitive/mood disturbances, respiratory symptoms, and infection. Mean length of stay was 11.6 days. Treatment response was variable. In 68%, of admission episodes there was stabilization or improvement, 75% were discharged home. In case of readmission, the mean interval has been 9.7 months. Time since diagnosis and admission triggers were not associated with outcome or death. Conclusion: Patients showed high symptom load contrasting with discharge rates and subsequent health care utilization. Brief multidisciplinary interventions might be helpful to preserve autonomy.